Literature DB >> 22208981

Discovery of internalizing antibodies to tumor antigens from phage libraries.

Yu Zhou1, James D Marks.   

Abstract

Phage antibody technology can be used to generate human antibodies to essentially any antigen. Many therapeutic target antigens are cell surface receptors, which can be challenging targets for antibody generation. In addition, for many therapeutic applications, one needs antibodies that not only bind the cell surface receptor but also are internalized into the cell upon binding. This allows use of the antibody to deliver a range of payloads into the cell to achieve a therapeutic effect. In this chapter, we describe how human phage antibody libraries can be selected directly on tumor cell lines to generate antibodies that bind cell surface receptors and which upon binding are rapidly internalized into the cell. Specific protocols show how to (1) directly select cell binding and internalizing antibodies from human phage antibody libraries, (2) screen the phage antibodies in a high-throughput flow cytometry assay for binding to the tumor cell line used for selection, (3) identify the antigen bound by the phage antibody using immunoprecipitation and mass spectrometry, and (4) direct cell binding and internalizing selections to a specific tumor antigen by sequential selection on a tumor cell line followed by selection on yeast displaying the target tumor antigen on the yeast surface.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22208981      PMCID: PMC4180867          DOI: 10.1016/B978-0-12-416039-2.00003-3

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  50 in total

1.  Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery.

Authors:  M E Hayes; D C Drummond; D B Kirpotin; W W Zheng; C O Noble; J W Park; J D Marks; C C Benz; K Hong
Journal:  Gene Ther       Date:  2006-04       Impact factor: 5.250

2.  Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells.

Authors:  Audrey Roth; Daryl C Drummond; Fraser Conrad; Mark E Hayes; Dmitri B Kirpotin; Christopher C Benz; James D Marks; Bin Liu
Journal:  Mol Cancer Ther       Date:  2007-10       Impact factor: 6.261

3.  Engineered antibody Fc variants with enhanced effector function.

Authors:  Greg A Lazar; Wei Dang; Sher Karki; Omid Vafa; Judy S Peng; Linus Hyun; Cheryl Chan; Helen S Chung; Araz Eivazi; Sean C Yoder; Jost Vielmetter; David F Carmichael; Robert J Hayes; Bassil I Dahiyat
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

4.  Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.

Authors:  Yu Zhou; Daryl C Drummond; Hao Zou; Mark E Hayes; Gregory P Adams; Dmitri B Kirpotin; James D Marks
Journal:  J Mol Biol       Date:  2007-05-10       Impact factor: 5.469

5.  Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation.

Authors:  M E Hayes; D C Drummond; K Hong; W W Zheng; V A Khorosheva; J A Cohen; Noble C O; J W Park; J D Marks; C C Benz; D B Kirpotin
Journal:  Mol Pharm       Date:  2006 Nov-Dec       Impact factor: 4.939

6.  Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.

Authors:  R Levy; C M Forsyth; S L LaPorte; I N Geren; L A Smith; J D Marks
Journal:  J Mol Biol       Date:  2006-10-03       Impact factor: 5.469

Review 7.  Development trends for monoclonal antibody cancer therapeutics.

Authors:  Janice M Reichert; Viia E Valge-Archer
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

Review 8.  Immunotoxins in the treatment of hematologic malignancies.

Authors:  Robert J Kreitman; Ira Pastan
Journal:  Curr Drug Targets       Date:  2006-10       Impact factor: 3.465

9.  Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies.

Authors:  Anne-Laure Goenaga; Yu Zhou; Christine Legay; Houcine Bougherara; Lan Huang; Bin Liu; Daryl C Drummond; Dmitri B Kirpotin; Christian Auclair; James D Marks; Marie-Alix Poul
Journal:  Mol Immunol       Date:  2007-05-10       Impact factor: 4.407

10.  Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.

Authors:  Bin Liu; Fraser Conrad; Audrey Roth; Daryl C Drummond; Jeff P Simko; James D Marks
Journal:  J Mol Med (Berl)       Date:  2007-06-07       Impact factor: 4.599

View more
  5 in total

1.  Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates.

Authors:  Kalli C Catcott; Molly A McShea; Carl Uli Bialucha; Kathy L Miller; Stuart W Hicks; Parmita Saxena; Thomas G Gesner; Mikias Woldegiorgis; Megan E Lewis; Chen Bai; Michael S Fleming; Seth A Ettenberg; Hans K Erickson; Nicholas C Yoder
Journal:  MAbs       Date:  2016-01-11       Impact factor: 5.857

2.  Discovery of internalizing antibodies to basal breast cancer cells.

Authors:  Yu Zhou; Hao Zou; Christina Yau; Lequn Zhao; Steven C Hall; Daryl C Drummond; Shauna Farr-Jones; John W Park; Christopher C Benz; James D Marks
Journal:  Protein Eng Des Sel       Date:  2018-01-01       Impact factor: 1.650

Review 3.  Targeted drug delivery for cancer therapy: the other side of antibodies.

Authors:  Michael A Firer; Gary Gellerman
Journal:  J Hematol Oncol       Date:  2012-11-09       Impact factor: 17.388

Review 4.  Nanoparticle-Based Contrast Agents for 129Xe HyperCEST NMR and MRI Applications.

Authors:  Jabadurai Jayapaul; Leif Schröder
Journal:  Contrast Media Mol Imaging       Date:  2019-11-22       Impact factor: 3.161

5.  Toxoplasmosis and Polygenic Disease Susceptibility Genes: Extensive Toxoplasma gondii Host/Pathogen Interactome Enrichment in Nine Psychiatric or Neurological Disorders.

Authors:  C J Carter
Journal:  J Pathog       Date:  2013-03-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.